Table 2

All Grade 3 or 4 AEs and additional AEs (all grades) occurring in more than 1 patient

AEAll grades
Grade 3 or 4
n%No. of eventsn%No. of events
Any AE 21 100 132 33 18 
    Infusion-related reactions 18 86 48 10 
    Cycle 1, day 1 (n = 21) 17 81   
    Cycle 1, day 8 (n = 20) 40   
    Cycle 2 (n = 19) 26     
    Cycle 3 or later (n = 16) 38     
Infections* 11 52 16    
Asthenia 38 10 10 
Diarrhea 24    
Thrombocytopenia 19 
Anorexia 19 
Weight loss 19    
Lymphopenia 14 14 
Fatigue 14    
Nausea 14    
Insomnia 14    
Neutropenia 10 10 
Anemia 10 
Sciatica 
Extrinsic vascular compression 
Tumor lysis syndrome 
Leukopenia 
Axillary pain 
Cerebrovascular accident    
AEAll grades
Grade 3 or 4
n%No. of eventsn%No. of events
Any AE 21 100 132 33 18 
    Infusion-related reactions 18 86 48 10 
    Cycle 1, day 1 (n = 21) 17 81   
    Cycle 1, day 8 (n = 20) 40   
    Cycle 2 (n = 19) 26     
    Cycle 3 or later (n = 16) 38     
Infections* 11 52 16    
Asthenia 38 10 10 
Diarrhea 24    
Thrombocytopenia 19 
Anorexia 19 
Weight loss 19    
Lymphopenia 14 14 
Fatigue 14    
Nausea 14    
Insomnia 14    
Neutropenia 10 10 
Anemia 10 
Sciatica 
Extrinsic vascular compression 
Tumor lysis syndrome 
Leukopenia 
Axillary pain 
Cerebrovascular accident    
*

The most common infection reported was bronchitis (n = 4). Herpesvirus infection occurred in 2 patients. All reported infections were grade 1 or 2.

The incidence of cerebrovascular accident was grade 5 and resulted in death. This 83-year-old patient had a low IgM level before treatment (115 mg/dL). IgM levels increased to 404 mg/dL after cycle 1, but returned to 107 mg/dL after cycle 2, 34 days before the cerebrovascular accident. Although no disease evaluation or IgM measurement was available before death, given this kinetic and the patient's underlying illness, the investigator judged that this event was unrelated to the study drug.

Close Modal

or Create an Account

Close Modal
Close Modal